research-articleIndian Journal of Pharmaceutical Education and ResearchVol. 58 | Issue 3 | 2024 | pp. 802–813Open access
Inhibiting Cancer Progression through Targeting HDAC2 with Novel Ligands: A Dynamic Insights through Virtual Screening and Simulation
- 1,
- 2,
- 1,
- 3,
- 4,
- 5,
- 5,
- 6,
- 7*
- 1 Department of Clinical Biochemistry, College of Medicine, King Khalid University, Abha, SAUDI ARABIA.
- 2 Department of Basic Medical Science, Faculty of Applied Medical Sciences, Al-Baha University, SAUDI ARABIA.
- 3 Department of Biochemistry, Faculty of Science, University of Tabuk, Tabuk 71491, SAUDI ARABIA.
- 4 Department of Surgery, King Khalid University, Abha, KINGDOM OF SAUDI ARABIA.
- 5 Department of Clinical Biochemistry, College of Medicine, King Khalid University, Abha, SAUDI ARABIA.
- 6 Department of Pharmacology, College of Medicine,Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, SAUDI ARABIA.
- 7 Almanac Life Science India Private Limited, New Delhi, INDIA.
Published in Indian Journal of Pharmaceutical Education and Research
Correspondence: Mohammed Tarique
Almanac Life Science India Private Limited, New Delhi, INDIA.
Email: tariqueaiims@gmail.com
Copyright: © 2024 Manuscript Technomedia. This is an open access article.
- Published:
- Jan 1, 2024
- Received:
- Dec 28, 2023
- Accepted:
- May 2, 2024
- DOI:
- 10.5530/ijper.58.3.88
How to cite
Patel, A. A., Alothaid, H., Mallick, A. K., Alalawy, A. I., Mirdad, R. T., Mirdad, M. T., Mirdad, M. T., Ahsan, M., & Tarique, M. (2024). Inhibiting Cancer Progression through Targeting HDAC2 with Novel Ligands: A Dynamic Insights through Virtual Screening and Simulation. Indian Journal of Pharmaceutical Education and Research, 58(3), 802–813. https://doi.org/10.5530/ijper.58.3.88
Abstract
Background
Cancer is a multifaceted disease characterized by uncontrolled cell growth and represents a significant global health challenge. The intricate origins of cancer involve various factors that may act independently or collectively, contributing to its initiation and progression and resulting in the dynamic nature of the disease.
Aim
The current focus of research is to elucidate the role of histone acetylation in cancer progression.
Materials and Methods
A key area of interest is histone deacetylation, which intensifies ion-based interactions between negatively charged DNA and positively charged histones. Histone deacetylation, specifically the removal of acetyl groups from histone proteins by Histone Deacetylase 2 (HDAC2), plays a pivotal role in regulating gene expression. The primary objective of this study was to identify molecular inhibitors targeting HDAC2 through Structure-Based Virtual Screening (SBVS) using an extensive MCULE chemical compound database. After the application of stringent filters, 100 promising compounds were selected for further investigation.
Results
Docking simulations using DockThor revealed 16 molecules with superior free binding energies compared to the control (entinostat). Subsequently, ten compounds meeting the Absorption, Distribution, Metabolism and Excretion (ADME) rules were chosen based on the Egan-Egg permeation predictive model. The top two ligands, along with the positive control entinostat, underwent a five-nanosecond molecular dynamics simulation. The evaluation criteria included toxicity profiling, physiochemical properties, lipophilicity, solubility, pharmacokinetics, druglikeness, medicinal chemistry attributes, Root Mean Square Deviation (RMSD), Root Mean Square Fluctuation (RMSF) and Radius of Gyration (Rg).
Conclusion
Through these analyses, ligand MCULE-5097730104-0-3 emerged as a promising HDAC2 inhibitor, exhibiting potential efficacy in combating cancer progression.
Keywords
Article metadata
| Title | Inhibiting Cancer Progression through Targeting HDAC2 with Novel Ligands: A Dynamic Insights through Virtual Screening and Simulation |
|---|---|
| Authors | Ayyub Ali Patel; Hani Alothaid; Ayaz Khurram Mallick; Adel Ibrahim Alalawy; Rasha Tarek Mirdad; Mahmoud Tarek Mirdad; Mohammed Tarek Mirdad; Marya Ahsan; Mohammed Tarique |
| Affiliations | Department of Clinical Biochemistry, College of Medicine, King Khalid University, Abha, SAUDI ARABIA.; Department of Basic Medical Science, Faculty of Applied Medical Sciences, Al-Baha University, SAUDI ARABIA.; Department of Biochemistry, Faculty of Science, University of Tabuk, Tabuk 71491, SAUDI ARABIA.; Department of Surgery, King Khalid University, Abha, KINGDOM OF SAUDI ARABIA.; Department of Clinical Biochemistry, College of Medicine, King Khalid University, Abha, SAUDI ARABIA.; Department of Pharmacology, College of Medicine,Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, SAUDI ARABIA.; Almanac Life Science India Private Limited, New Delhi, INDIA. |
| Corresponding author | tariqueaiims@gmail.com |
| Journal | Indian Journal of Pharmaceutical Education and Research |
| Volume / Issue | Vol. 58, Issue 3 (2024) |
Also in this issue
- QSAR Based Drug Repurposing: A New Paradigm in Breast Cancer Researchpp. 695–708
- A Systematic Review on Association of Oxidative Stress in Rheumatoid Arthritis Based on Cross-Sectional Case-Control Studiespp. 709–721
- Methodology and Results Analysis of Effect and Economic Evaluations Related to Pharmaceutical Care Practice in China: A Recent Reviewpp. 722–729
- Tablet Compression Optimization of Ivabradine Sustained-Release Tablet Using Full Factorial Designpp. 730–735
- A Novel Targeted Nanoliposomal Atorvastatin Transdermal Patch Assisted with Solid Microneedles for Improved Bioavailabilitypp. 736–750